Investor Overview

2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.

Read More >

Latest News

Neovasc Reducer™ Featured In Germany’s Second Largest National Newspaper

> read full release

Archive >

Presentations and Events

REDUCER - I interim results presented by
Pr. Verheye at PCR e-course 2020


view here >

Neovasc Presentation - June 2020


.pptx format (excel) > .pdf format (acrobat) >

First Quarter 2020 Earnings Call From May 7, 2020


view here >

Neovasc Provides Update on Second Quarter Results

Company to Report Full Financial Results
on August 6, 2020

 

Read More >

Financial Report Archives

2020 Financial Reports
  • Q1
  • Q2
  • Q3
  • Q4

News Release Archives

2020 News Releases

Share Information

Auditor
Grant Thornton LLP, Vancouver, BC

Legal Counsel
Blakes LLP, Vancouver, BC

Transfer Agent
Computershare, Vancouver, BC

Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com

To automatically receive news updates

register now